The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000698370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
15/05/2026
Date registered
Help: Date registered
11/06/2026
Date last updated
Help: Date last updated
11/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
11/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Does nervous system function predict rehabilitation outcomes in people with patellar tendinopathy?
Scientific title
Do pain or motor neurophysiological factors predict response to 12-weeks progressive exercise rehabilitation in people with patellar tendinopathy?
Additional trial identifiers [1] 317159 0
None
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
patellar tendinopathy 341892 0
Condition category
Condition code
Musculoskeletal 337951 337951 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
12-weeks contemporary progressive exercise rehabilitation program:

Participants will complete a 12-week progressive exercise rehabilitation program that closely follows a contemporary, evidence-based protocol. This will progress through four 'levels': isometric exercise, isotonic exercise, stretch-shorten cycle (energy-storage) exercise, and return to sport exercise. Progress is based on strict pain and function criteria.

Following the initial assessment, participants will be provided with thorough, standardised education by the chief investigator, covering:
• The benefits of exercise therapy;
• How to monitor pain irritability using pain provoked by prescribed exercises;
• The structure and application of progressive-exercise rehabilitation, including:
o Program stages and progression criteria;
o Detailed descriptions of gym-based resistance exercises and home-based alternatives;
o Guidelines for modifying activity (e.g., training and competition) based on pain irritability.

Participants will be provided access to gym facilities required to complete the rehabilitation program, with an agreement in place for 12-weeks membership with a gym chain, who have sites locations situated throughout east and south-east Melbourne to maximise accessibility for the targeted recruitment region. Additionally, home-based alternate exercises will be provided to improve feasibility of adherence to the exercise program.

The intervention will be delivered by experienced physiotherapy clinicians who have undergone comprehensive training in key intervention components, including progressive-exercise rehabilitation. Intervention delivery will be supported and monitored using PhysiApp (Physitrack, London, UK), a freely available, HIPAA-compliant, cloud-based mobile phone application. Clinicians will access the corresponding clinician-facing software (Physitrack). Participants will be supported to install PhysiApp on their personal mobile device and to navigate functions required for this trial (e.g., logging exercises). Individualised exercise programs, matched to their rehabilitation 'level', will be delivered via the application. This will include written exercise details, in addition to videos demonstrating appropriate exercise performance/technique recorded for this trial.

Exercise mode, frequency, and durations per level:
• Level 1 (isometric stage): Primary exercises include the single-leg isometric knee extension using a leg extension or leg press machine (or a double- or single-leg isometric wall sit as a home alternative). Sessions are completed every second day. The starting dosage is 5 sets of 45-second holds, which gradually progresses within the level to 5 sets of 20-second holds as weight is increased. Each session is anticipated to take approximately 20 minutes to complete.
• Level 2 (isotonic stage): Primary exercises include the single-leg isotonic knee extension (or a walking lunge or step-up as home alternatives). Level 1 exercises are also continued on the same day (completed after isotonic movements). Sessions are performed every second day. The starting dosage is 4 sets of 15 repetitions, which progresses by reducing repetitions and increasing load until 4 sets of 6 repetitions are achieved. Each session is anticipated to take approximately 30-45 minutes to complete.
• Level 3 (energy-storage stage): Exercises consist of stretch-shorten cycle movements such as jump squats, split jump squats, and box jumps, alongside continued Level 1 and 2 maintenance exercises. Sessions are performed every third day. The dosage starts at 3 sets of 6 repetitions and progresses up to 6 sets of 6 repetitions. Each session is anticipated to take approximately 45-60 minutes to complete.
• Level 4 (sport-specific stage): Exercises involve an individualised approach matched directly to the participant's recreation or sport (e.g., jumping, dribbling, and cutting drills for a basketball player). Level 1 and 2 exercises continue on the first day post-sport-specific training. Sessions are performed every second to third day. The starting duration is approximately 30 minutes per session, building gradually until full training duration is reached.

Exercise intensity targets and assessment:
Exercise intensity is formally evaluated following the completion of each exercise using a modified Rated Perceived Exertion (mRPE) scale ranging from 1 to 10.
• For Levels 1 and 2, the target level of exercise intensity is vigorous to very hard, explicitly aiming for a target mRPE of 8/10 or higher by the end of each set (indicating near-fatigue).
• For Level 3, intensity is judged by movement velocity and power rather than muscle fatigue. It starts at a target velocity rating of 7/10 (high velocity/70% of perceived maximum speed) and aims to progress to a target of 9/10 or higher (extremely high velocity) with no velocity loss by the final repetition.
• For Level 4, exercises begin at a self-perceived moderate intensity, targeting approximately 70% of match intensity (corresponding to a mRPE rating of 7/10 [hard]), before gradually progressing to 'full' maximum athletic intensity.

Participant app interaction and review format/timing:
Participants are not required to interact with PhysiApp for a designated minimum daily duration; instead, they use the app at their own discretion to guide their prescribed workout sessions and must log their exercise data (sets, repetitions, load, mRPE, and pain scores) immediately following each completed session.

Clinical review and progress assessments do not follow a fixed bi-weekly or tri-weekly timeline. Instead, data logged by participants is monitored remotely by clinicians on a continuous basis. Clinicians formally evaluate individual progress once a week via the Physitrack desktop portal to determine if within-level progression criteria are met. When a participant successfully satisfies the strict pain and functional criteria required to advance to the next overarching rehabilitation 'level' (e.g., maintaining pain = 3/10 on the Numeric Rating Scale for an entire week at the maximum level dosage), a progression review is triggered. While the initial physical examination screening is conducted face-to-face to confirm diagnosis and eligibility, subsequent level-progress reviews are conducted remotely.

Clinicians will utilise the Physitrack system’s integrated video-conferencing function to review the participant when ready to progress from one level to the next, confirm readiness, and provide detailed technical instructions for this upcoming exercise level. All updated program details (when progressed within a level, or between levels) are immediately reflected on the participant's PhysiApp mobile app interface.

Clinicians will monitor adherence via the exercise sessions logged on PhysiApp; if participants miss more than one planned session in a week-period, the clinician will follow up via the Physitrack system’s secure messaging function. This function will also be used to alert participants to weekly within-level program updates, and for feedback or urgent enquiries, and will be checked daily by clinicians. Automatic reminders will be sent via PhysiApp for each exercise session to encourage adherence.
Intervention code [1] 334058 0
Rehabilitation
Description of the comparator or control
None
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345403 0
Patellar tendinopathy-specific disability
Timepoint [1] 345403 0
Baseline, within 7 days post 12-week progressive rehabilitation program completion
Primary outcome [2] 345405 0
endogenous pain facilitation
Timepoint [2] 345405 0
Baseline, within 7 days of post-intervention motor neurophysiological assessment (which will take place within 7 days post 12-week progressive rehabilitation program completion)
Secondary outcome [1] 461552 0
endogenous pain inhibition at the affected patellar tendon
Timepoint [1] 461552 0
Baseline, within 7 days of post-intervention motor neurophysiological assessment (which will take place within 7 days post 12-week progressive rehabilitation program completion)
Secondary outcome [2] 461553 0
Exercise induced hypoalgesia assessed using the single leg decline squat
Timepoint [2] 461553 0
Baseline, within 7 days of post-intervention motor neurophysiological assessment (which will take place within 7 days post 12-week progressive rehabilitation program completion)
Secondary outcome [3] 461555 0
Knee extension maximum voluntary isometric force
Timepoint [3] 461555 0
Baseline, within 7 days post 12-week progressive rehabilitation program completion
Secondary outcome [4] 461571 0
Motor neurophysiological excitability
Timepoint [4] 461571 0
Baseline, within 7 days post 12-week progressive rehabilitation program completion
Secondary outcome [5] 461642 0
Tendon thickness
Timepoint [5] 461642 0
Baseline, within 7 days of post-intervention motor neurophysiological assessment (which will take place within 7 days post 12-week progressive rehabilitation program completion)
Secondary outcome [6] 461643 0
tendon stiffness
Timepoint [6] 461643 0
Baseline, within 7 days of post-intervention motor neurophysiological assessment (which will take place within 7 days post 12-week progressive rehabilitation program completion)
Secondary outcome [7] 461644 0
Exercise fidelity
Timepoint [7] 461644 0
Weekly while participants are in the second level of this intervention (i.e., the level in which participants are first prescribed isotonic exercise
Secondary outcome [8] 461645 0
Kinesiophobia
Timepoint [8] 461645 0
Baseline, within 7 days post 12-week progressive rehabilitation program completion
Secondary outcome [9] 461647 0
Adherence
Timepoint [9] 461647 0
Immediately post 12-week progressive rehabilitation program completion
Secondary outcome [10] 462265 0
Endogenous pain inhibition at the lateral elbow epicondyle
Timepoint [10] 462265 0
Baseline, within 7 days of post-intervention motor neurophysiological assessment (which will take place within 7 days post 12-week progressive rehabilitation program completion)
Secondary outcome [11] 462278 0
Exercise induced hypoalgesia assessed using pressure pain threshold at the affected patellar tendon
Timepoint [11] 462278 0
Baseline, within 7 days of post-intervention motor neurophysiological assessment (which will take place within 7 days post 12-week progressive rehabilitation program completion)
Secondary outcome [12] 462279 0
Exercise induced hypoalgesia assessed using pressure pain threshold at the lateral elbow epicondyle
Timepoint [12] 462279 0
Baseline, within 7 days of post-intervention motor neurophysiological assessment (which will take place within 7 days post 12-week progressive rehabilitation program completion)
Secondary outcome [13] 462293 0
Silent period duration
Timepoint [13] 462293 0
Baseline, within 7 days post 12-week progressive rehabilitation program completion
Secondary outcome [14] 462296 0
Short interval cortical inhibition
Timepoint [14] 462296 0
Baseline, within 7 days post 12-week progressive rehabilitation program completion
Secondary outcome [15] 462301 0
Intracortical facilitation
Timepoint [15] 462301 0
Baseline, within 7 days post 12-week progressive rehabilitation program completion
Secondary outcome [16] 462303 0
Long interval intracortical inhibition
Timepoint [16] 462303 0
Baseline, within 7 days post 12-week progressive rehabilitation program completion
Secondary outcome [17] 462304 0
Lumbar evoked potentials
Timepoint [17] 462304 0
Baseline, within 7 days post 12-week progressive rehabilitation program completion
Secondary outcome [18] 462306 0
maximum compound action potential
Timepoint [18] 462306 0
Baseline, within 7 days post 12-week progressive rehabilitation program completion
Secondary outcome [19] 462307 0
Reticulospinal excitability
Timepoint [19] 462307 0
Baseline, within 7 days post 12-week progressive rehabilitation program completion
Secondary outcome [20] 462440 0
Pain catastrophsing
Timepoint [20] 462440 0
Baseline, within 7 days post 12-week progressive rehabilitation program completion
Secondary outcome [21] 462441 0
Pain Self Efficacy
Timepoint [21] 462441 0
Baseline, within 7 days post 12-week progressive rehabilitation program completion
Secondary outcome [22] 462442 0
Anxiety and depression
Timepoint [22] 462442 0
Baseline, within 7 days post 12-week progressive rehabilitation program completion
Secondary outcome [23] 462443 0
Quality of life
Timepoint [23] 462443 0
Baseline, within 7 days post 12-week progressive rehabilitation program completion
Secondary outcome [24] 462445 0
Motor unit activation
Timepoint [24] 462445 0
Baseline, within 7 days post 12-week progressive rehabilitation program completion
Secondary outcome [25] 462446 0
Motor unit rate coding
Timepoint [25] 462446 0
Baseline, within 7 days post 12-week progressive rehabilitation program completion

Eligibility
Key inclusion criteria
- Participants aged 18 years or greater
- Clinical diagnosis of patellar tendinopathy - diagnosis will be based on:
o Self-reported pain localised to the inferior pole of the patella, confirmed by pain on palpation by the outcome assessor
o The presence of clinical features consistent with patellar tendinopathy including: symptom duration 3 months or greater, following gradual onset; pain provoked in a load-dependent manner during activities that place strain on the patellar tendon (e.g., running, jumping or descending stairs); and pain aggravated immediately following periods of inactivity (e.g., upon waking or after prolonged sitting).
- Typical tendinopathic changes detected via ultrasound imaging (Mindray M7, Shenzhen, China), including tendon thickening (>60mm) and hypoechoic regions.
- A minimum pain score of 2/10 on a numerical rating scale (NRS; where 0 = no pain, and 10 = worst pain imaginable) during a single-leg decline squat.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Any other painful condition besides patellar tendinopathy (e.g., low back pain, acute muscle strain; current or within the preceding six months) that persisted longer than one week or required healthcare consultation (e.g., a general practitioner, physiotherapist, or any other allied healthcare professional).
• History of patellar tendon rupture or surgery,
• Injection (e.g., corticosteroid, platelet rich plasma or any other pharmaceutical agent) to the knee region in the previous six months.
• Diagnosed with type I or II diabetes, neurological conditions or inherited connective tissue disorders, or if they have any metal implants in the cranial region.
• Failure to meet safet requirements on the transcranial magnetic stimulation (TMS) safety screening questionnaire.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
To address the primary aim, we will use hierarchical multiple linear regression to determine whether the addition of endogenous pain inhibition and facilitation improve prediction of 12 week VISA P scores beyond a baseline covariates model.

To address the secondary aim, we will use linear mixed-effects models to estimate within-person association between changes in VISA P and concurrent motor neurophysiological adaptation. For each motor neurophysiological outcome, time and VISA P will be fit as predictors, allowing quantification of concurrent improvement in VISA P and neurophysiological outcomes. To control for mulplicity, corrections to results associated with secondary analysis.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321744 0
University
Name [1] 321744 0
School of Primary and Allied Health Care Seeding Grant (Monash University)
Country [1] 321744 0
Australia
Primary sponsor type
University
Name
Monash University
Address
Country
Australia
Secondary sponsor category [1] 324584 0
None
Name [1] 324584 0
Address [1] 324584 0
Country [1] 324584 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320291 0
Monash University Human Research Ethics Committee
Ethics committee address [1] 320291 0
Ethics committee country [1] 320291 0
Australia
Date submitted for ethics approval [1] 320291 0
31/07/2025
Approval date [1] 320291 0
01/10/2025
Ethics approval number [1] 320291 0
48519

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149982 0
Dr Patrick Vallance
Address 149982 0
Monash University Peninsula Campus, Moorooduc Hwy, Frankston VIC 3199
Country 149982 0
Australia
Phone 149982 0
+61 456877333
Fax 149982 0
Email 149982 0
Contact person for public queries
Name 149983 0
Patrick Vallance
Address 149983 0
Monash University Peninsula Campus, Moorooduc Hwy, Frankston VIC 3199
Country 149983 0
Australia
Phone 149983 0
+61 456877333
Fax 149983 0
Email 149983 0
Contact person for scientific queries
Name 149984 0
Patrick Vallance
Address 149984 0
Monash University Peninsula Campus, Moorooduc Hwy, Frankston VIC 3199
Country 149984 0
Australia
Phone 149984 0
+61 456877333
Fax 149984 0
Email 149984 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Journal publication or its supplementary materials: De-identified individual participant data will be including as appropriate in the corresponding journal publication (in the main text or as a supplementary file)

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.